Swiss National Bank Boosts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Swiss National Bank boosted its position in Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 5.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 139,500 shares of the biotechnology company’s stock after purchasing an additional 7,400 shares during the period. Swiss National Bank owned about 0.23% of Blueprint Medicines worth $7,046,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its position in shares of Blueprint Medicines by 414.2% during the first quarter. Steward Partners Investment Advisory LLC now owns 617 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 497 shares in the last quarter. Prospera Financial Services Inc purchased a new stake in shares of Blueprint Medicines during the first quarter worth $42,000. Nisa Investment Advisors LLC lifted its position in shares of Blueprint Medicines by 50.7% during the second quarter. Nisa Investment Advisors LLC now owns 684 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 230 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Blueprint Medicines by 717.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 850 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 746 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Blueprint Medicines during the first quarter worth $95,000.

Blueprint Medicines Stock Up 0.9 %

BPMC opened at $43.57 on Wednesday. The business’s fifty day simple moving average is $54.41 and its 200 day simple moving average is $57.69. Blueprint Medicines Co. has a 52 week low of $40.78 and a 52 week high of $111.78. The stock has a market cap of $2.61 billion, a PE ratio of -3.60 and a beta of 0.67. The company has a quick ratio of 6.79, a current ratio of 6.99 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

BPMC has been the topic of several recent research reports. Raymond James dropped their target price on Blueprint Medicines from $133.00 to $115.00 and set a “strong-buy” rating on the stock in a research report on Wednesday, August 3rd. The Goldman Sachs Group lowered their price objective on Blueprint Medicines from $143.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, November 3rd. JMP Securities lowered their price objective on Blueprint Medicines from $152.00 to $114.00 and set a “market outperform” rating on the stock in a research report on Friday, November 4th. Piper Sandler lowered their price objective on Blueprint Medicines from $65.00 to $59.00 in a research report on Tuesday, August 2nd. Finally, Stifel Nicolaus increased their price objective on Blueprint Medicines from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 18th. Two analysts have rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $83.67.

Insider Activity

In related news, CEO Kate Haviland acquired 1,100 shares of Blueprint Medicines stock in a transaction dated Thursday, November 3rd. The shares were purchased at an average cost of $43.98 per share, with a total value of $48,378.00. Following the completion of the purchase, the chief executive officer now owns 92,281 shares of the company’s stock, valued at $4,058,518.38. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Fouad Namouni sold 3,477 shares of the firm’s stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $67.30, for a total transaction of $234,002.10. Following the transaction, the insider now directly owns 52,797 shares of the company’s stock, valued at $3,553,238.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kate Haviland acquired 1,100 shares of Blueprint Medicines stock in a transaction dated Thursday, November 3rd. The shares were bought at an average cost of $43.98 per share, for a total transaction of $48,378.00. Following the completion of the purchase, the chief executive officer now directly owns 92,281 shares of the company’s stock, valued at approximately $4,058,518.38. The disclosure for this purchase can be found here. Insiders own 3.42% of the company’s stock.

Blueprint Medicines Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Read More

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMCGet Rating).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.